Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Evox Therapeutics

- PMLiVE

FDA rejects Sarepta’s new Duchenne drug over safety fears

FDA gave no warnings of concerns, says chief exec

- PMLiVE

Duchenne UK backs Evox dystrophin delivery project

Funding will drive preclinical studies on dystrophin-bearing exosomes

- PMLiVE

Redmile and Google help Evox raise £35.5m for exosome pipeline

It is reported that GV contributed £10m of the total

- PMLiVE

Sarepta soars on positive Duchenne data

Trial results position Sarepta as a “leader in the field” according to analysts

- PMLiVE

Tony de Fougerolles joins Evox Therapeutics as CEO

He succeeds Dr Per Lundin who stays at the firm as COO

- PMLiVE

FDA reviewer unimpressed with PTC’s Translarna

Finds the muscular dystrophy treatment's evidence to be 'not persuasive'

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Santhera facing long delay for muscular dystrophy drug in US

FDA rejects accelerated marketing application for Raxone to await phase II trial results

Biomarin

BioMarin gives up on muscular dystrophy drug

Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa

Biomarin

BioMarin files muscular dystrophy drug in EU

Drisapersen could be the first ‘exon-skipping’ therapy

- PMLiVE

Sarepta seeks new CEO but says eteplirsen is on track

Garabedian will be temporarily replaced by CMO Ed Kaye

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links